Do patients with schizophrenia exhibit aberrant salience?

J P Roiser, K E Stephan, H E M den Ouden, T R E Barnes, K J Friston, E M Joyce, J P Roiser, K E Stephan, H E M den Ouden, T R E Barnes, K J Friston, E M Joyce

Abstract

Background: It has been suggested that some psychotic symptoms reflect 'aberrant salience', related to dysfunctional reward learning. To test this hypothesis we investigated whether patients with schizophrenia showed impaired learning of task-relevant stimulus-reinforcement associations in the presence of distracting task-irrelevant cues.

Method: We tested 20 medicated patients with schizophrenia and 17 controls on a reaction time game, the Salience Attribution Test. In this game, participants made a speeded response to earn money in the presence of conditioned stimuli (CSs). Each CS comprised two visual dimensions, colour and form. Probability of reinforcement varied over one of these dimensions (task-relevant), but not the other (task-irrelevant). Measures of adaptive and aberrant motivational salience were calculated on the basis of latency and subjective reinforcement probability rating differences over the task-relevant and task-irrelevant dimensions respectively.

Results: Participants rated reinforcement significantly more likely and responded significantly faster on high-probability-reinforced relative to low-probability-reinforced trials, representing adaptive motivational salience. Patients exhibited reduced adaptive salience relative to controls, but the two groups did not differ in terms of aberrant salience. Patients with delusions exhibited significantly greater aberrant salience than those without delusions, and aberrant salience also correlated with negative symptoms. In the controls, aberrant salience correlated significantly with 'introvertive anhedonia' schizotypy.

Conclusions: These data support the hypothesis that aberrant salience is related to the presence of delusions in medicated patients with schizophrenia, but are also suggestive of a link with negative symptoms. The relationship between aberrant salience and psychotic symptoms warrants further investigation in unmedicated patients.

Figures

Fig. 1
Fig. 1
The Salience Attribution Test. Participants were required to respond to the black square as quickly as possible. On 50% of trials, participants won more money for quicker responses. The conditioned stimuli appearing before the response are coloured either red or blue.
Fig. 2
Fig. 2
Adaptive salience based on latency in patients with schizophrenia and controls. * Patients exhibited reduced adaptive salience relative to controls (p=0.035). Values are means and standard errors.
Fig. 3
Fig. 3
Adaptive salience based on subjective reinforcement probability ratings in patients with schizophrenia and controls. * Patients exhibited reduced adaptive salience relative to controls (p=0.002). Values are means and standard errors.
Fig. 4
Fig. 4
Aberrant salience calculated from subjective reinforcement probability ratings in patients with schizophrenia. * Patients with delusions exhibited significantly greater aberrant salience than those without delusions (p=0.005). Values are means and standard errors.
Fig. 5
Fig. 5
Relationship between the sum of global scores from the Scale for the Assessment of Negative Symptoms (SANS) and aberrant salience (calculated from subjective reinforcement probability ratings). Aberrant salience correlated significantly with negative symptoms in patients with schizophrenia (r=0.51, p=0.020).

References

    1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacology. 2004;7:S1–S5. (Suppl. 1),
    1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences USA. 2000;97:8104–8109.
    1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research. 1990;3:247–251.
    1. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS) University of Iowa Press; Iowa City: 1981.
    1. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS) University of Iowa Press; Iowa City: 1983.
    1. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berlin) 2007;191:391–431.
    1. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Research Reviews. 1998;28:309–369.
    1. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC. Putatively psychosis-prone subjects 10 years later. Journal of Abnormal Psychology. 1994;103:171–183.
    1. Claridge G. Single indicator of risk for schizophrenia: probable fact or likely myth? Schizophrenia Bulletin. 1994;20:151–168.
    1. Cohen BD. Motivation and performance in schizophrenia. Journal of Abnormal Psychology. 1956;52:186–190.
    1. Cutmore TR, Beninger RJ. Do neuroleptics impair learning in schizophrenic patients? Schizophrenia Research. 1990;3:173–186.
    1. Dayan P, Balleine BW. Reward, motivation, and reinforcement learning. Neuron. 2002;36:285–298.
    1. Garety PA, Hemsley DR, Wessely S. Reasoning in deluded schizophrenic and paranoid patients. Biases in performance on a probabilistic inference task. Journal of Nervous and Mental Disorders. 1991;179:194–201.
    1. Garmezy N. Stimulus differentiation by schizophrenic and normal subjects under conditions of reward and punishment. Journal of Personality. 1952;20:253–276.
    1. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41:1–24.
    1. Heerey EA, Gold JM. Patients with schizophrenia demonstrate dissociation between affective experience and motivated behavior. Journal of Abnormal Psychology. 2007;116:268–278.
    1. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U. et al.Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 1995;346:1130–1131.
    1. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Australian and New Zealand Journal of Psychiatry. 2000;34:221–236.
    1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine (Monograph Supplement) 1992;20:1–97.
    1. Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, Crawley AP, Kapur S. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology. 2008;33:473–479.
    1. Joyce EM, Hutton SB, Mutsatsa SH, Barnes TR. Cognitive heterogeneity in first-episode schizophrenia. British Journal of Psychiatry. 2005;187:516–522.
    1. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006;29:409–416.
    1. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry. 2003;160:13–23.
    1. King R, Barchas JD, Huberman BA. Chaotic behavior in dopamine neurodynamics. Proceedings of the National Academy of Sciences USA. 1984;81:1244–1247.
    1. Knutson B, Bjork JM, Fong GW, Hommer D, Mattay VS, Weinberger DR. Amphetamine modulates human incentive processing. Neuron. 2004;43:261–269.
    1. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D‘Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences USA. 1996;93:9235–9240.
    1. Mason O, Linney Y, Claridge G. Short scales for measuring schizotypy. Schizophrenia Research. 2005;78:293–296.
    1. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Archives of General Psychiatry. 2004;61:134–142.
    1. Miller R. Striatal dopamine in reward and attention: a system for understanding the symptomatology of acute schizophrenia and mania. International Review of Neurobiology. 1993;35:161–278.
    1. Milstein DM, Dorris MC. The influence of expected value on saccadic preparation. Journal of Neuroscience. 2007;27:4810–4818.
    1. Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, Jones PB, Bullmore ET, Robbins TW, Fletcher PC. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Molecular Psychiatry. 2008;13:267–276.
    1. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature. 2006;442:1042–1045.
    1. Robbins TW. Synthesizing schizophrenia: a bottom-up, symptomatic approach. Schizophrenia Bulletin. 2005;31:854–864.
    1. Schooler NR. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatrica Scandinavica. 1994;380:21–26.
    1. Schultz W. Dopamine neurons and their role in reward mechanisms. Current Opinion in Neurobiology. 1997;7:191–197.
    1. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275:1593–1599.
    1. Seymour B, Daw N, Dayan P, Singer T, Dolan R. Differential encoding of losses and gains in the human striatum. Journal of Neuroscience. 2007;27:4826–4831.
    1. Shaner A. Delusions, superstitious conditioning and chaotic dopamine neurodynamics. Medical Hypotheses. 1999;52:119–123.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry. 1998;59:22–57. (Suppl. 20),
    1. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. American Journal of Psychiatry. 1976;133:197–202.
    1. Stefanis NC, Van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Hantoumi I, Stefanis CN. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biological Psychiatry. 2004;56:510–515.
    1. Taylor SF, Phan KL, Britton JC, Liberzon I. Neural response to emotional salience in schizophrenia. Neuropsychopharmacology. 2005;30:984–995.
    1. Waltz JA, Frank MJ, Robinson BM, Gold JM. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biological Psychiatry. 2007;62:756–764.
    1. Wechsler D. Wechsler Adult Intelligence Scale – Revised. The Psychological Corporation; New York: 1981.
    1. Wechsler D. Wechsler Test of Adult Reading Manual. The Psychological Corporation; San Antonio, TX: 2001.
    1. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends in Neuroscience. 2004;27:683–690.
    1. Wise RA. Dopamine, learning and motivation. Nature Reviews Neuroscience. 2004;5:483–494.
    1. Wyvell CL, Berridge KC. Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward ‘wanting’ without enhanced ‘liking’ or response reinforcement. Journal of Neuroscience. 2000;20:8122–8130.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry. 1978;133:429–435.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe